ClinicalTrials.gg
Active, not recruitingNCT03406338Updated Apr 16, 2025

Fasciectomy vs Collagenase Injection in Recurrent Dupuytren Disease

A Phase 4 interventional study of Fasciectomy and Collagenase Clostridium Histolyticum in Dupuytren Disease of Finger, sponsored by Region Skane. Active, not recruiting at 1 site in Sweden. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-04-16.

Sponsored by Region Skane · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

This randomized controlled trial will compare the outcome of surgery (fasciectomy) with that of local injection of Collagenase Clostridium Histolyticum in patients with recurrent finger joint contracture after previous treatment with Surgery, collagenase injection or needle fasciotomy. Half of the participants will be treated with surgery while the other half will receive collagenase injection.

Read the detailed description

No definitive cure for Dupuytren disease (DD) currently exists and recurrence of finger contractures after treatment is common. Surgical fasciectomy is considered the standard treatment method for patients with recurrence. However, the procedure is associated with a high incidence of complications. Injection of Collagenase Clostridium Histolyticum into Dypuytren cords causing the contracture is a non-surgical treatment for DD and has been shown to be a safe and effective method. Most studies regarding collagenase injection have involved first-time treatment. Efficacy of collagenase injection in patients with recurrent DD, beyond the immediate effect, has not yet been determined. This randomized trial will compare the outcome of surgical fasciectomy and collagenase injection in treating patients with finger joints contracture due to recurrent DD. The study is a single-center randomized controlled trial. Patients referred to an orthopedic department are screened for eligibility. The inclusion criteria are recurrence of DD in one or more fingers after previous treatment with fasciectomy, collagenase injection or needle fasciotomy, a passive extension deficit ≥30 degrees in the metacarpophalangeal (MCP) and/or proximal interphalangeal (PIP) joint in a previously treated finger, and a palpable cord believed to cause the recurrent contracture. A total of 56 patients will be randomized (computer-generated randomization list, stratified according to type of previous treatment and affected finger), to either surgical fasciectomy or collagenase injection. A blinded hand therapist will measure range of motion (including active and passive extension deficit) at baseline and 3 months, 12 months, 24 months and 60 months after treatment. The primary outcomes are the total active extension deficit (MCP plus PIP) at 3 months and the proportion of patients with contracture worsening ≥20 degrees in the treated finger joint at 2 years compared to 3 months. The secondary outcomes include total passive extension deficit, the 11-item disabilities of the arm, shoulder and hand (QuickDASH) score, EuroQol 5-dimensions (EQ-5D) index, cold intolerance symptom severity score, palmar pain score, pain visual analog scale (VAS) score, satisfaction VAS score, adverse events and costs.

02

Conditions studied

  • Dupuytren Disease of Finger
03

In context

Lead sponsor

Region Skane is the lead sponsor of 386 studies on the registry; 122 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Seeking treatment for recurrence of Dupuytren´s contracture in at least one finger.
  • Passive extension deficit of 30 degrees or greater in the metacarpophalangeal and/or proximal interphalangeal joint in a finger previously treated with surgical fasciectomy, collagenase injections, or needle fasciotomy.
  • Palpable cord in the palm and/or affected finger causing the recurrent contracture.
  • No Surgery, collagenase injection or needle fasciotomy in the finger with recurrent contracture in the past 12 months.

Exclusion criteria

Exclusion Criteria:

  • Medical comorbidities that constitute a for surgical fasciectomy or collagenase injection.
  • Signs of nerve or vascular injury in the affected finger.
  • Osteoarthritis in the metacarpophalangeal and/or proximal interphalangeal joint joint in the affected finger
  • Complications after the previous treatment, such as infection or complex regional pain syndrome (CRPS).
  • Previous trauma or other surgery involving the affected finger.
  • More than 2 previous surgeries, collagenase injections or needle fasciotomies in the affected finger.
  • Examining surgeon deems further fasciectomy inappropriate or potentially associated with very high complication risk, for example in severe contracture and/or severe scarring after the previous surgeries and considers salvage procedures (such as amputation) as the more appropriate treatment.
  • Patient refusal to participate
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
60 participants (actual)

Study arms

  • Active comparator
    Surgical fasciectomy

    Fasciectomy according to usual care (surgery), implying excision of Dupuytren's cords and tissues to release the finger joint contractures

    Procedure: Fasciectomy

  • Experimental
    Collagenase Clostridium Histolyticum

    Injection of 0.8 mg collagenase clostridium histolyticum into multiple spots in the Dupuytren cords followed by finger manipulation 1-2 days later to release the finger joint contractures

    Drug: Collagenase Clostridium Histolyticum

Interventions

  • ProcedureFasciectomy

    Surgical excision of Dupuytren cords causing finger joint contractures. Surgery done under regional or general anesthesia. Additional procedures (such as capsulotomy or skin graft) done if surgeon deemed necessary.

    Also known as: Surgery

  • Injection of Collagenase into the Dupuytren cord after local anesthesia (nerve block) followed 24-48 hours later by finger manipulation after local anesthesia

    Also known as: Non-surgical treatment

06

What researchers measure

Primary outcomes

  1. Total active extension deficit (metacarpophalangeal plus proximal interphalangeal joints)

    Extension deficit of the metacarpophalangeal and interphalangeal joints of the treated finger measured with hand-held goniometer (0 degrees indicates no extension deficit)

    Time frame: Change from baseline to 3 months

  2. Proportion of patients with worsening in total active extension deficit ≥20 degrees

    Extension deficit of the metacarpophalangeal and interphalangeal joints of the treated finger measured with hand-held goniometer (0 degrees indicates no extension deficit)

    Time frame: 24 months compared to 3 months

Secondary outcomes

  1. 11-item disabilities of the arm, shoulder and hand (QuickDASH) score

    A patient-reported outcome measure of activity limitations related to upper extremity disorders, with total score range from 0 (best) to 100 (worst)

    Time frame: Change over time from from baseline, 3 weeks, 6 weeks, 3 months, 12 months, 24 months and 60 months

  2. EuroQoL 5-dimensions (EQ-5D) Index

    Health-status and quality-of-life patient-reported measure, consists of 5 items, a single weighted score, the EQ-5D index, is calculated from the 5 dimensions, ranging from -0.594 (worst) to 1.0 (perfect health)

    Time frame: Change over time from from baseline, 3 weeks, 6 weeks, 3 months, 12 months, 24 months and 60 months

  3. Pain score

    Visual analog scale of pain in the treated hand, score range from 0 (best) to 100 (worst)

    Time frame: Change over time from from baseline, 3 weeks, 6 weeks, 3 months, 12 months, 24 months and 60 months

  4. Satisfaction score

    Visual analog scale of patient satisfaction with treatment outcome, score range from 0 (best) to 100 (worst)

    Time frame: 3 weeks, 6 weeks, 3 months, 12 months, 24 months and 60 months

  5. Adverse events

    All observed and reported adverse events will be recorded on a standard form. Serious adverse events include nerve, artery or tendon damage, deep infection, complex regional pain syndrome and any complications requiring surgery or hospital admission.

    Time frame: Anytime during 24 months after treatment

  6. Costs

    Total treatment cost, direct (medications, surgery, materials, visits etc) and indirect (sick leave related to the treatment)

    Time frame: From baseline through 24 months

  7. Total active motion

    Sum of active range of motion of metacarpophalangeal, proximal intephalangeal and distal interphalangeal joints of the treated finger

    Time frame: Change from baseline to 3 months, 12 months, 24 months and 60 months

  8. Total active extension deficit (metacarpophalangeal plus proximal interphalangeal joints)

    Active extension deficit of the metacarpophalangeal and interphalangeal joints of the treated finger measured with hand-held goniometer (0 degrees indicates no extension deficit)

    Time frame: Change from baseline to 12 months, 24 months and 60 months

  9. Proportion of patients with worsening in total active extension deficit ≥20 degrees

    Extension deficit of the metacarpophalangeal and interphalangeal joints of the treated finger measured with hand-held goniometer (0 degrees indicates no extension deficit)

    Time frame: 60 months compared to 3 months

  10. Palmar pain score

    2-item scale inquiring about pain in the palm and related activity limitations, total score range 0 (best) to 100 (worst)

    Time frame: Change over time from baseline to 3 weeks, 6 weeks, 3 months, 12 months, 24 months and 60 months.

  11. Cold intolerance symptom severity score

    6-item scale inquiring about symptoms of cold intolerance, total score range 4 (best) to 100 (worst)

    Time frame: Change from baseline to 3 weeks, 6 weeks, 3 months, 12 months, 24 months and 60 months.

  12. Total passive extension deficit (metacarpophalangeal plus proximal interphalangeal joints)

    Passive extension deficit of the metacarpophalangeal and interphalangeal joints of the treated finger measured with hand-held goniometer (0 degrees indicates no extension deficit)

    Time frame: Change from baseline to 24 months and 60 months

07

Study locations

1 site
  • Department of Orthopedics Hässleholm-Kristianstad
    Hässleholm, SE 28125, Sweden
08

References and documents

Publications

  • Nordenskjold J, Lauritzson A, Walden M, Kopylov P, Atroshi I. Surgical fasciectomy versus collagenase injection in treating recurrent Dupuytren disease: study protocol of a randomised controlled trial. BMJ Open. 2019 Feb 25;9(2):e024424. doi: 10.1136/bmjopen-2018-024424. PubMed 30808670 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Mar 2018 to primary completion in Sep 2024, 77 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 14, 2018
First posted
Jan 23, 2018
StartActual
Mar 20, 2018
Primary completionActual
Sep 1, 2024
CompletionEst.
Sep 2027
Last update
Apr 16, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 16, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03406338
Lead sponsor
Region Skane
Responsible party
Isam Atroshi (Professor, Region Skane) — Principal investigator
First posted
Jan 23, 2018
Start date
Mar 20, 2018
Primary completion
Sep 1, 2024
Completion
Sep 2027 (estimated)
Last update
Apr 16, 2025

Study contacts

Isam Atroshi, MD, PhD
principal investigator · Lund University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Apr 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Microbial Collagenase

Start the discussion